Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab Announces $250 Million Private Placement

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab Limited has announced a $250 million private placement through a securities purchase agreement. The company will sell 11,340,000 American Depositary Shares at a price of $22.04 each. This financing aims to bolster Zai Lab's operations and growth initiatives.

Market Sentiment Analysis

POSITIVE FACTORS

  • Zai Lab raised $250 million through a PIPE financing.
  • The investment involves the sale of 11,340,000 ADSs.
  • Each ADS is priced at $22.04.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+64%
120-day peak, hindsight
Typical move
2.3%
average across 15 past catalysts
Cash runway
~27 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares (“ADSs”), each representing ten ordinary shares of the Company, to certain investors in a private investment in public equity (“PIPE”) financing. The purchase price of each ADS is $22.04. Gross proceeds from the PIPE financing are expe

Frequently Asked Questions

What is the total amount raised by Zai Lab?

Zai Lab raised $250 million through a private placement.

How many American Depositary Shares were sold?

The company sold 11,340,000 American Depositary Shares.

What is the price per ADS in the financing?

Each American Depositary Share is priced at $22.04.

What is the purpose of the private placement?

The financing aims to support Zai Lab's operations and growth initiatives.

ShareAdd on Google
Tags: ZLAB Zai Lab private placement PIPE financing American Depositary Shares biopharma
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$618M liquidity · $21M/mo burn
~27 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Extensive-Stage Small Cell Lung Cancer →

Catalyst track record

+64%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →